Home/Pipeline/CUR-002

CUR-002

Solid Tumors

Phase 1/2Active, Dose Escalation

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active, Dose Escalation

Company

Curatis

About Curatis

Curatis is a Swiss public biotech focused on developing innovative therapeutics for rare diseases and oncology. Its core asset is a proprietary technology platform designed to identify novel targets and generate optimized drug candidates. The company's strategy centers on advancing its clinical-stage programs, CUR-001 and CUR-002, through proof-of-concept while expanding its preclinical pipeline. With a modest market valuation, Curatis represents a high-risk, high-reward investment opportunity in the specialized European biotech sector.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active